<DOC>
	<DOCNO>NCT00579137</DOCNO>
	<brief_summary>This study discover whether child severe combine immunodeficiency disease ( SCID ) primary immunodeficiency disorder ( PID ) satisfactory treatment stem cell transplantation ( SCT ) exist safely effectively transplant HLA mismatch ( one haplotype ) relate donor unrelated match mismatch ( one antigen ) donor , leukocytolytic monoclonal antibody ( MAb ) Fludarabine sole conditioning agent . Three monoclonal antibody use combination . Two rat IgG1 ( immunoglobulin G1 ) antibody direct two contiguous epitope CD45 ( common leucocyte ) antigen . They safely administer part condition regimen 12 patient receive allograft ( HLA match mismatch ) center . They produce transient depletion &gt; 90 % circulate leucocyte . The third MAb Campath 1H , humanize rat anti-CD52 MAb . Campath 1H , Alemtuzumab , license treat B-cell chronic lymphocytic leukemia ( B-CLL ) recently safely give center part sub-ablative conditioning regimen patient malignant disease . Because MAb produce profound immunosuppression significant , though transient , myelodestruction believe may useful sole condition regimen patient SCID , use conventional chemotherapeutic agent condition may produce aggravate unacceptable even lethal short term toxicity . We anticipate MAb mediate subablative conditioning permit engraftment high percentage patient little immediate long term toxicity . Campath IH persist vivo several day administration present transplant period deplete donor T cell partial GvHD prophylaxis . Additional Graft versus Host Disease ( GvHD ) prophylaxis may provide administration FK506 .</brief_summary>
	<brief_title>Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders</brief_title>
	<detailed_description>Donor Stem Cell Processing Mismatched Donors : Harvested peripheral blood stem cell enrich CD34 cell use CliniMACS CD34 Reagent system , accord Center Cell Gene Therapy ( CAGT ) SOPs . Stem Cell Transplant Conditioning Campath-1H give 3 daily intravenous infusion follow Anti-CD45 give four daily intravenous infusion complete two day prior stem cell infusion . Diphenydramine administer i.v . q4h period course Campath Anti-CD45 infusion . Day 8 Campath 1H per CAGT SOP Fludarabine 10 kg less : 1 mg/kg ; &gt; 10 kg : 30 mg/m2 7 Campath 1H per CAGT SOP Fludarabine 10 kg less : 1 mg/kg ; &gt; 10 kg : 30 mg/m2 6 Campath 1H per CAGT SOP Fludarabine 10 kg less : 1 mg/kg ; &gt; 10 kg : 30 mg/m2 5 YTH 24/54 400ug/kg 6 hr Fludarabine 10 kg less : 1 mg/kg ; &gt; 10 kg : 30 mg/m2 4 YTH 24/54 400ug/kg 6 hr Fludarabine 10 kg less : 1 mg/kg ; &gt; 10 kg : 30 mg/m2 3 YTH 24/54 400ug/kg 6 hr 2 YTH 24/54 400ug/kg 6 hr 1 rest 0 Stem Cell Infusion Campath 1H Infusion- Campath dose weight base : patient le 15 killograms ( kg ) administer Campath 3 mg ; patient &gt; 15 kg 30 kg administer Campath 5 mg ; patient &gt; 30 kg administer Campath 10 mg. Campath dose administer per CAGT SOP . Anti-CD45- Infusion Anti-CD45 infusion administer accord CAGT SOPs . 3 ml heparinized blood drawn 48 hr post Anti-CD45 evaluate free Anti-CD45 level plasma . This estimation use determine whether treatment irradiate leukocyte require bone marrow infuse . GVHD Prophylaxis- GVHD prophylaxis achieve positive selection CD34 result &gt; 3 log T cell depletion . Previous report indicate low frequency severe ( Grade II/IV ) GVHD haploidentical transplant recipient receive stem cell population contain &lt; 5 x 10 CD3 positive T cell . We hope achieve level CD34 enrichment protocol . However , pharmacologic prophylaxis add CD34 select product contain 5 x 10 CD3+ve T cells/kg recipient weight . In addition , Campath 1H persists recipient circulation immediate transplant period contribute anti-GVHD activity , vivo . Patients develop acute chronic GVHD manage accord CAGT SOPs .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients diagnosis : Severe combine immunodeficiency disease This include patient whose SCID characterize gene specific mutation well patient clinically severe combine immunodeficiency without define genetic cause diagnosis determine combination clinical course lymphocyte quantification function assay . OR Severe primary immunodeficiency disorder , include undefined T cell deficiency disorder , WiskottAldrich syndrome , severe immunodeficiency satisfactory conventional therapy exist . Availability HLA mismatch ( one haplotype ) family member HLA match mismatch ( one antigen ) unrelated donor . Creatinine &lt; 2.5 x normal age . Life expectancy great 6 week Lansky/Karnofsky great equal 70 % Patients HLA match related donor Patients symptomatic cardiac disease , evidence significant cardiac disease echocardiogram ( i.e. , shorten fraction le 25 % ) Patients known allergy rat serum product Patients severe infection evaluation Principal Investigator preclude ablative chemotherapy successful transplantation HIV positive Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Severe Combined Immunodeficiency Disease</keyword>
	<keyword>Severe Primary Immunodeficiency Disorder</keyword>
	<keyword>Undefined T cell Deficiency Disorder</keyword>
	<keyword>Wiskott-Aldrick Syndrome</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>